Binimetinib Dosage

Medically reviewed by Drugs.com. Last updated on Aug 13, 2018.

• Overview
• Side Effects
• Dosage
• Professional
• Interactions
• More

Usual Adult Dose for Melanoma - Metastatic

45 mg orally every 12 hours in combination with encorafenib until disease progression or unacceptable toxicity

Comments:
-Refer to the encorafenib prescribing information for encorafenib dosing information.
-This drug may be taken with or without food.
-Do not take a missed dose within 6 hours of the next dose.
-Do not take an additional dose if vomiting occurs after administration but continue with the next scheduled dose.

Use: In combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test

Renal Dose Adjustments

No adjustment recommended.

Liver Dose Adjustments

-Mild hepatic impairment (total bilirubin greater than 1 and less than or equal to 1.5 x the upper limit of normal (ULN) and any AST or total bilirubin less than or equal to ULN and AST greater than ULN: No adjustment recommended.
-Moderate (total bilirubin greater than 1.5 and less than or equal to 3 × ULN and any AST) or severe (total bilirubin levels greater than or equal to 3 × ULN and any AST) hepatic impairment: The recommended dose is 30 mg orally 2 times a day.

Dose Adjustments

If encorafenib is permanently discontinued, discontinue this drug.

Recommended Dose Reductions for Adverse Reactions:
-First dose reduction: 30 mg orally every 12 hours
-Subsequent modification: Permanently discontinue this drug if unable to tolerate 30 mg orally every 12 hours.

DOSE ADJUSTMENTS:
CARDIOMYOPATHY:
-Asymptomatic, absolute decrease in LVEF of greater than 10% from baseline that is also below lower limit of normal (LLN): Withhold this drug for up to 4 weeks; evaluate LVEF every 2 weeks. Resume this drug at a reduced dose if LVEF is at or above the lower limit or normal AND absolute decrease from baseline is 10% or less AND patient is asymptomatic. If the LVEF does not recover within 4 weeks permanently discontinue this drug.
-Symptomatic congestive heart failure or absolute decrease in LVEF or greater than 20% from baseline that is also below LLN: Permanently discontinue this drug.
VENOUS THROMBOEMBOLISM:
-Uncomplicated deep venous thrombosis (DVT) or pulmonary embolism (PE): Withhold this drug. If improves to Grade 0 or 1, resume at a reduced dose. If no improvement, permanently discontinue this drug.
-Life threatening PE: Permanently discontinue this drug.
SEROUS RETINOPATHY:
-Symptomatic serous retinopathy/retinal pigment epithelial detachments: Withhold this drug for up to 10 days. If improves and becomes asymptomatic, resume at the same dose. If not improved, resume at a lower dose level or permanently discontinue this drug.
RETINAL VEIN OCCLUSION (RVO):
-Any grade: Permanently discontinue this drug.
UVEITIS:
-Grade 1, 2, or 3: If Grade 1 or 2 does not respond to specific ocular therapy, or for Grade 3 uveitis, withhold this drug for up to 6 weeks. If improved, resume at same or reduced dose. If not improved, permanently discontinue this drug.
-Grade 4: Permanently discontinue this drug.
INTERSTITIAL LUNG DISEASE:
-Grade 2: Withhold this drug for up to 4 weeks. If improved to Grade 0 or 1, resume a reduced dose. If not resolved within 4 weeks, permanently discontinue this drug.
-Grade 3 or 4: Permanently discontinue this drug.
HEPATOTOXICITY:
-Grade 2 AST or ALT increased: Maintain the dose. If no improvement within 2 weeks, withhold this drug until improved to Grade 0 or 1 or to pretreatment/baseline levels and then resume at the same dose.
-First occurrence of Grade 3 AST or ALT increased: Withhold this drug for up to 4 weeks. If improves to Grade 0 or 1 or to pretreatment/baseline levels, resume at reduced dose. If no improvement, permanently discontinue this drug.
-Recurrent Grade 3 AST or ALT increased: Consider permanently discontinuing this drug.
-First occurrence of Grade 4 AST or ALT increased: Permanently discontinue this drug OR withhold this drug for up to 4 weeks. If improves to Grade 0 or 1 or to pretreatment/baseline levels, then resume at a reduced dose. If no improvement, permanently discontinue this drug.
-Recurrent Grade 4 AST or ALT increased: Permanently discontinue this drug.
RHABDOMYOLYSIS OR CREATINE PHOSPHOKINASE (CPK) ELEVATIONS:
-Grade 4 asymptomatic CPK elevation OR any Grade CPK elevation with symptoms or with renal impairment: Withhold this drug for up to 4 weeks. If improved to Grade 0 or 1 resume at a reduced dose. If not resolved within 4 weeks, permanently discontinue this drug.
DERMATOLOGIC:
-Grade 2: If no improvement within 2 weeks, withhold this drug until Grade 0 to 1. Resume at same dose if first occurrence or reduce dose if recurrent.
-Grade 3: Withhold this drug until Grade 0 or 1. Resume at same dose if first occurrence or reduce dose if recurrent.
-Grade 4: Permanently discontinue this drug.
OTHER ADVERSE REACTIONS (INCLUDING HEMORRHAGE):
-Recurrent Grade 2 or first occurrence of any Grade 3: Withhold this drug for up to 4 weeks. If improved to Grade 0 or 1 resume at a reduced dose. If not resolved within 4 weeks, permanently discontinue this drug.
-First occurrence of any Grade 4: Permanently discontinue this drug OR withhold this drug for up to 4 weeks. If improves to Grade 0 or 1 or to pretreatment/baseline levels, then resume at a reduced dose. If no improvement, permanently discontinue this drug.

Precautions

CONTRAINDICATIONS:
-None

This drug is not recommended for use in children.

Consult WARNINGS section for additional precautions.

Dialysis

This drug is 95% bound to plasma proteins; therefore, it is unlikely to be removed by hemodialysis.

Other Comments

Administration advice:
-Refer to the encorafenib prescribing information for encorafenib dosing information.
-This drug may be taken with or without food.
-Do not take a missed dose within 6 hours of the next dose.
-Do not take an additional dose if vomiting occurs after administration but continue with the next scheduled dose.

Storage requirements:
-Store at 20C to 25C (68F to 77F); excursions permitted between 15C and 30C (59F and 86F).

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Related questions

• What is Mektovi used to treat?

Medical Disclaimer